Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

It may not be quite time to throw out the psychiatrist’s couch, but Oxford Professor of Psychiatry Andrea Cipriani is hoping his research might transform the traditional approach to mental health treatment.

Professor Andrea Cipriani

Working with his multidisciplinary team at the Oxford Precision Psychiatry Lab, the Italian-born professor is conducting evidence-based research into treatment for depression; if successful, this research could transform the way people with mental health conditions are treated by medical practitioners in the NHS. 

Rather than embarking on long trial-and-error course, Professor Cipriani’s research looks to introduce a more rigorous, reliable approach to find the right treatment for each individual, using a shared decision-making process, which takes into account patients’ personal preferences and values.

The research will encompass information from 40,000 cases of depression from hundreds of randomised trials, as well as real world data about treatment impact on 700,000 NHS patients. The aim is to identify patterns within individual treatment journeys -  such as what has been proven to work or has been better tolerated for people with specific characteristics. In a field where – 'unfairly' – commonly prescribed medications are believed  not to be substantially different, this personalised approach will help clinicians and patients decide together which treatment suits them best, when they agree to start an antidepressant. Results from this research can save time and suffering for the patients, and also money and resources for the NHS, improving outcomes for all parties.

Read the full article on the University of Oxford website

Similar stories

New insights into chemogenetic designer drugs to enhance our study of behaviour

A collaborative team of researchers in DPAG and Pharmacology led by Dr Lukas Krone have uncovered striking new data demonstrating that two widely used designer drugs used to turn populations of neurons on and off in the brain cause unexpected effects on sleep. These results demonstrate a critical need to improve chemogenetic approaches in behavioural studies.

Ensuring LGBTQI+ people are treated fairly in mental health data

Andrey Kormilitzin outlines a new participatory study aimed at improving AI to take account of LGBTQI+ people so that their needs are better met by mental health services.

Community play packs inspire families to be more playful at home

A project led by Alex Hendry working with Oxford Brookes has engaged with parents and early years practitioners in a bid to help families spend more time playing with their children.

Major trials to test effectiveness of cannabidiol on psychosis

Global study involving three clinical trials will investigate the effectiveness of cannabidiol (CBD) in treating people with psychosis or psychotic symptoms, thanks to a multi-million pound grant to Oxford University.

Friendship and mental health in adolescents

Tanya Manchanda's new paper investigates the role of friendship on the mental health outcomes of adolescents